GleamWall
中文EN

NMRA Neumora Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1885522 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.4%
TTM EPS YoY27.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-252.7%
ROA-139.6%
ROIC (approx.)-332.4%
Asset turnover—

Leverage & solvency

Liabilities / assets80.5%
Debt / equity6.11x
Current ratio4.08x
Interest coverage-34.16x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-16.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$22.61M$29.28M$38.60M$44.67M$40.52M$38.72M$52.15M$45.91M
SG&A expense$10.79M$12.91M$14.27M$13.81M$12.18M$15.32M$18.79M$17.01M
Operating income-$33.41M-$42.19M-$52.86M-$58.48M-$57.70M-$54.04M-$70.94M-$62.92M
Interest expense$1.44M$1.43M$1.44M$1.17M$534,000$307,000$0$0
Pretax income-$34.44M-$43.08M-$53.43M-$59.45M-$56.76M-$52.71M-$67.89M-$58.82M
Income tax$0$0$30,000$0$0$25,000$105,000$0
Net income-$34.44M-$43.08M-$53.46M-$59.45M-$56.76M-$52.73M-$67.99M-$58.82M
EBITDA-$33.41M-$42.18M-$52.86M-$58.47M-$57.68M-$54.02M-$70.78M-$62.77M
EPS (basic)-0.18-0.23-0.30—-0.35-0.33-0.42—
EPS (diluted)-0.18-0.23-0.30—-0.35-0.33-0.42—
Weighted avg. shares (diluted)187.90M185.16M179.87M—161.84M161.69M161.45M—
Balance sheet
Cash & equivalents$85.65M$116.83M$147.07M$182.53M$129.07M$124.52M$126.86M$142.15M
Short-term investments————$42.45M$93.06M$122.49M$165.43M
Current assets$94.75M$124.87M$153.43M$190.54M$177.08M$222.91M$254.87M$314.06M
PP&E, net—$25,000$32,000$40,000$80,000$87,000$982,000$1.14M
Total assets$95.05M$125.25M$153.88M$191.05M$177.83M$223.82M$256.75M$316.97M
Current liabilities$23.19M$27.78M$30.11M$32.45M$25.84M$21.16M$28.38M$29.89M
Short-term debt$60.00M$60.00M$60.00M$60.00M$20.00M$20.00M——
Long-term debt$53.30M$52.91M$52.96M$54.53M$19.56M$19.45M—$0
Total debt$113.30M$112.91M$112.96M$114.53M$39.56M$39.45M—$0
Total liabilities$76.50M$80.73M$83.20M$87.18M$45.67M$40.95M$28.38M$29.91M
Shareholders' equity$18.55M$44.52M$70.68M$103.87M$132.16M$182.88M$228.36M$287.06M
Net debt$27.65M-$3.92M-$34.11M-$68.00M-$89.51M-$85.07M—-$142.15M
Shares outstanding———174.26M———161.71M
Cash flow statement
Operating cash flow-$33.44M-$39.53M-$46.40M-$47.95M-$46.63M-$52.40M-$59.45M-$50.34M
Investing cash flow-$71,000$0$71,000$42.65M$51.32M$30.40M$44.16M-$98.80M
Financing cash flow$2.33M$9.29M$10.88M$58.77M-$136,000$18.46M$0$15.57M
Depreciation & amortization$3,000$7,000$8,000$9,000$23,000$19,000$157,000$157,000
Stock-based compensation$6.14M$7.18M$7.41M$7.41M$5.98M$7.17M$9.32M$9.90M

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.